4.4 Review

Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review

Journal

NEUROLOGY AND THERAPY
Volume 11, Issue 4, Pages 1489-1517

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s40120-022-00392-2

Keywords

Attention-deficit; hyperactivity disorder; Lisdexamfetamine; Mechanism of action; Methylphenidate; Molecular characterisation; Neurotransmitter imbalance

Funding

  1. Takeda Farmaceutica Espana S.A

Ask authors/readers for more resources

Attention-deficit/hyperactivity disorder (ADHD) is a common childhood-onset neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity. ADHD is often accompanied by other comorbid diseases and can interfere with functioning and development. The treatment of ADHD involves a multidisciplinary approach, including both medication and non-pharmacological interventions. Stimulant medications such as methylphenidate (MPH) and lisdexamfetamine dimesylate (LDX) are commonly used as first-line pharmacological treatments. However, the underlying molecular mechanisms of ADHD and its treatments are not well understood, and further research is needed to improve our understanding and develop more effective interventions.
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood-onset neurodevelopmental disorder characterised by persistent inattention, hyperactivity and impulsivity. Moreover, ADHD is commonly associated with other comorbid diseases (depression, anxiety, bipolar disorder, etc.). The ADHD symptomatology interferes with subject function and development. The treatment of ADHD requires a multidisciplinary approach based on a combination of non-pharmacological and pharmacological treatments with the aim of ameliorating the symptomatology; among first-line pharmacological treatments are stimulants [such as methylphenidate (MPH) and lisdexamfetamine dimesylate (LDX)]. In this review we explored recent ADHD- and stimulants-related literature, with the aim of compiling available descriptions of molecular pathways altered in ADHD, and molecular mechanisms of current first-line stimulants MPH and LDX. While conducting the narrative review, we applied structured search strategies covering PubMed/MEDLINE database and performed handsearching of reference lists on the results of those searches. The aetiology and pathophysiology of ADHD are incompletely understood; both genetic and environmental factors have been associated with the disorder and its grade of burden, and also the relationship between the molecular mechanisms of pharmacological treatments and their clinical implications. The lack of comprehensive understanding of the underlying molecular pathology makes both the diagnosis and treatment difficult. Few published studies evaluating molecular data on the mechanism of action (MoA) of MPH and LDX on ADHD are available and most of them are based on animal models. Further studies are necessary to improve the knowledge of ADHD pathophysiology and how the MoAs of MPH and LDX differentially modulate ADHD pathophysiology and control ADHD symptomatology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available